Neue Aspekte zur aktuellen Therapie von Oropharynxkarzinomen
Standard
Neue Aspekte zur aktuellen Therapie von Oropharynxkarzinomen : Highlights vom ASCO-Kongress 2012. / Loewenthal, M; Vitez, E; Laban, S; Münscher, A; Güldenzoph, B; Knecht, R; Busch, C-J.
in: HNO, Jahrgang 60, Nr. 11, 01.11.2012, S. 951-6.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Neue Aspekte zur aktuellen Therapie von Oropharynxkarzinomen
T2 - Highlights vom ASCO-Kongress 2012
AU - Loewenthal, M
AU - Vitez, E
AU - Laban, S
AU - Münscher, A
AU - Güldenzoph, B
AU - Knecht, R
AU - Busch, C-J
PY - 2012/11/1
Y1 - 2012/11/1
N2 - Beside the surgical treatment of head and neck cancer, the concept of organ and function preserving therapy of locally advanced HNSCC (head and neck squamous cell carcinoma) especially of oropharyngeal origin is becoming increasingly important. The comparison of induction chemotherapy plus chemoradiation and primary concomitant chemoradiation has recently been the subject of randomized clinical trials. New combinations of different (chemo)radiation regimens and targeted therapies are also under investigation for HNSCC. Molecular markers predicting treatment efficacy as well as new potential targets are also being evaluated in several clinical trials. The good prognosis of HPV-associated HNSCC has sparked efforts to deintensify treatment to minimize therapy-related toxicities. The impact of specific therapies is growing due to the increasing incidence of young patients with HPV-positive carcinomas.
AB - Beside the surgical treatment of head and neck cancer, the concept of organ and function preserving therapy of locally advanced HNSCC (head and neck squamous cell carcinoma) especially of oropharyngeal origin is becoming increasingly important. The comparison of induction chemotherapy plus chemoradiation and primary concomitant chemoradiation has recently been the subject of randomized clinical trials. New combinations of different (chemo)radiation regimens and targeted therapies are also under investigation for HNSCC. Molecular markers predicting treatment efficacy as well as new potential targets are also being evaluated in several clinical trials. The good prognosis of HPV-associated HNSCC has sparked efforts to deintensify treatment to minimize therapy-related toxicities. The impact of specific therapies is growing due to the increasing incidence of young patients with HPV-positive carcinomas.
KW - Humans
KW - Medical Oncology
KW - Oropharyngeal Neoplasms
U2 - 10.1007/s00106-012-2597-8
DO - 10.1007/s00106-012-2597-8
M3 - SCORING: Zeitschriftenaufsatz
C2 - 23114540
VL - 60
SP - 951
EP - 956
JO - HNO
JF - HNO
SN - 0017-6192
IS - 11
ER -
